Bayer Schering To Develop Imaging Compounds To Detect Neurodegenerative Diseases
Bayer Schering Pharma AG has signed a license and option agreement with Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd., and the National Institute of Radiological Sciences, Japan, to develop novel imaging compounds for the detection of neurodegenerative diseases.
The diseases include Alzheimer's disease, Parkinson's disease and other disorders also associated with neuroinflammation such as multiple sclerosis.
Under the terms of the agreement Bayer Schering Pharma receives worldwide exclusive rights to develop and market the respective products for use with PET scanning technology.
Hans Maier, Head of Business Unit Diagnostic Imaging at Bayer Schering Pharma, said, "We are convinced that innovations in molecular imaging have the potential to fundamentally improve the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease."